SPINK1 and myelodysplastic syndrome: TCP, an irreversible inhibitor, is being used in clinical practice among patients with AML and MDS, showing promising effects either alone or in combination with all-trans-retinoic acid in phase I/II clinical trials, with overall response rates exceeding 20%.621,622 Building on TCP’s structure, novel inhibitors like ORY-1001, ORY-2001, GSK-2879552, INCB059872, and IMG-7289 have been developed, which also bind irreversibly to LSD1.623 These advancements have broadened the spectrum of treatable diseases with LSD1 inhibitors.